HTR2A and schizophrenia: The rationale for the use of the receptor-blocking antidepressants in schizophrenia is the presumption that combination of an inhibitor of the 5HT2 receptor (antidepressant) with a relatively pure D2 blocker (FGA) would result in a clinical effect resembling that of the SGAs, with possible additional benefits in terms of efficacy and tolerability (Berk et al., 2001; Joffe et al., 2009).